

Interventions for quitting vaping

Findings from November 2025 Cochrane review

There is limited guidance on the best ways to stop using nicotine containing vapes (otherwise known as e-cigarettes) and ensure long-term abstinence, whilst minimising the risk of tobacco smoking and other unintended consequences.

This briefing document brings you the most up-to-date information from our Cochrane review on the potential benefits and harms of interventions to help people who vape to achieve long-term vaping abstinence. This review is funded by Cancer Research UK

Key findings

- Text message-based interventions may help young people to stop vaping when compared to no or minimal support; however, more evidence is needed.
- Varenicline may help people to stop vaping when compared to no or minimal support; however, more evidence is needed.
- We don't know whether other interventions can help people to stop vaping for six months or more.
- We need more information on potential harms of interventions and whether they cause people to return to, or take up, smoking tobacco

About Cochrane reviews

Cochrane reviews bring together the best available evidence from research and systematically review this information to determine the benefits and risks of treatments. Cochrane is a non-profit organisation. Cochrane Reviews are internationally recognized as the highest standard in evidence-based reviews.

Why this topic is important?

Nicotine vapes expose users to less of the substances that cause disease that are present in tobacco cigarettes. However, vaping is likely to cause more harm than not vaping. Some people vape nicotine to help them quit smoking; however, some people who vape nicotine have never smoked. People may want to stop using vapes containing nicotine, but find it difficult due to nicotine's addictive properties.

Which interventions could help people stop vaping?

Medicines including nicotine replacement therapy (gums, patches, etc.), varenicline, bupropion, and cytisine are already used to help people stop smoking and could be used for stopping vaping. Behavioural interventions could include counselling, text messaging, online support, print-based information and programmes that change vaping behaviour or vape characteristics.

How many studies did we find?

This Cochrane systematic review included 15 studies, representing 5800 participants. In order to keep the information as up-to-date as possible we will search monthly for new evidence - a living systematic review. The November 2025 review includes search findings up to 1st July 2025. Six new studies were added at this update, two of these investigated new comparisons: i) smartphone app + text messaging; ii) higher versus lower dose NRT.

Unanswered questions & future research

More randomized controlled trials are needed with long-term follow up. As data continue to emerge we will update our analyses to ensure decision-makers have the best available evidence to hand when considering how to advise people to stop using vapes

MARCH 2026 SEARCH UPDATE...Our search carried out on 1st March 2026 identified 1 new study, 2 new ongoing studies & 5 linked reports. Between August 2025 & February 2026 searches identified 1 new study, 7 new ongoing studies & 7 papers linked to studies included in the review. The findings from these searches will be incorporated into the next update of our review.

**For all references and the most up to date 2025 Cochrane Review follow this [link](#).
For further information please visit our [webpage](#).**

The process

Databases were searched for randomized trials recruiting people of any age using nicotine containing vapes, regardless of tobacco smoking status. Studies had to test an intervention designed to support people to quit vaping, and plan to measure at least one of our outcomes. The main outcomes were:

- How many people stopped using nicotine vapes at least 6 months after study start (also measured between 3 & 6 months);
- Change in tobacco smoking at least 6 months after study start (also measured between 3 & 6 months);
- How many people experienced reporting serious adverse events (SAEs) and adverse events (AEs) of treatment, at least one week after treatment started;
- Change in biological markers (e.g. blood pressure; biomarkers of harm)

Summary of findings tables were made for main comparisons and outcomes. We identified 15 RCTs.

Funding

Of the 15 studies that reported funding information four were funded by the manufacturer or provider of the intervention (Caponnetto 2023; Graham 2021; Graham 2024; Rigotti 2024).

Summary of findings tables

Summary of findings tables were made for main comparisons and outcomes, see following pages.

1. Combination NRT compared to control for nicotine vaping cessation
2. Cytisine compared to placebo for nicotine vaping cessation
3. Varenicline compared to control for nicotine vaping cessation
4. Nicotine/vaping reduction compared to minimal support for nicotine vaping cessation
5. Text message-based interventions compared to no/minimal support for nicotine vaping cessation in young people (13-24 years)

GRADE ratings were used to evaluate certainty in the evidence and can be interpreted as follows.

Grade Working Group grades of evidence

High certainty: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

GRADE (Grading of Recommendations, Assessment, Development and Evaluations)

See our full review



[Cochrane IQV review](#)

Visit our webpage



[Webpage](#)

Listen to our podcast



[Podcasts](#)

1. Summary of Findings: Combination NRT compared to control for nicotine vaping cessation

Combination NRT compared to control for nicotine vaping cessation

Patient or population: people who use nicotine vapes
 Setting: USA
 Intervention: combination NRT
 Comparison: control

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Certainty of the evidence (GRADE)
	Risk with control	Risk with combination NRT			
Vaping cessation at 6 months or longer follow up: 6 months	Study population		RR 0.96 (0.73 to 1.25)	214 (2 RCTs)	⊕⊖⊖⊖ Very low ^{a, b}
	50 per 100	48 per 100 (36 to 62)			
Change in combustible tobacco use at 6 months or longer – not reported	Study population		RR 0.99 (0.71 to 1.37)	198 (1 RCT)	⊕⊖⊖⊖ Very low ^{b, c}
	43 per 100	42 per 100 (30 to 59)			
Number of participants reporting serious adverse events at follow up: 3 months Assessed via self-report and medical records	Study population		Not pooled**	706 (2 RCTs)	⊕⊖⊖⊖ Very low ^{a, d}
	Not pooled**	Not pooled**			

*The estimated number of events in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

** We did not calculate relative or absolute effects as there were no events across study arms in either study.

CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

^a Downgraded two levels due to risk of bias: both studies contributing were judged to be at high risk of bias.

^b Downgraded two levels due to imprecision: 95% CI incorporates the potential for no effect, plus both a potential benefit and harm of the intervention.

^c Downgraded two levels due to risk of bias: the one study contributing was judged to be at high risk of bias.

^d Downgraded two levels due to imprecision: no events recorded across study arms.

2. Summary of Findings: Cytisine compared to placebo for nicotine vaping cessation

Cytisine compared to placebo for nicotine vaping cessation					
Patient or population: people who use nicotine vapes					
Setting: USA					
Intervention: cytisine					
Comparison: placebo					
Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Certainty of the evidence (GRADE)
	Risk with placebo	Risk with cytisine			
Vaping cessation at 6 months or longer – not reported	Study population			No studies reported this outcome	
	-				
Change in combustible tobacco use at 6 months or longer – not reported	Study population			No studies reported this outcome	
	-				
Number of participants reporting serious adverse events at follow up: 4 months Assessed via self-report and medical records	Study population		Not pooled**	159 (1 RCT)	⊕⊕⊖⊖ Low ^a
	Not pooled**	Not pooled**			

*The estimated number of events in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

** It was not possible to calculate relative or absolute effects as no events were reported across study arms.

CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

^a Downgraded two levels due to imprecision. No events were reported across study arms.

3. Summary of Findings: Varenicline compared to control for nicotine vaping cessation

Varenicline compared to control for nicotine vaping cessation

- Patient or population: people who use nicotine vapes
 Setting: Italy and USA
 Intervention: varenicline
 Comparison: control

Outcomes	Anticipated absolute effects [†] (95% CI)		Relative effect (95% CI)	N ^o of participants (studies)	Certainty of the evidence (GRADE)
	Risk with control	Risk with varenicline			
Vaping cessation at 6 months or longer follow up: 6 months	Study population 11 per 100	31 per 100 (15 to 63)	RR 2.71 (1.33 to 5.49)	315 (2 RCTs)	⊕⊕⊕⊖ LOW ^a
Change in combustible tobacco use at 6 months or longer – not reported	Study population			No studies reported this outcome	
Number of participants reporting serious adverse events at follow up: range 3 months to 6 months Assessed via self-report and medical records	Study population 1 per 100	2 per 100 (0 to 12)	RR 2.82 (0.45 to 17.59)	304 (4 RCTs)	⊕⊕⊕⊖ LOW ^b

[†]The estimated number of events in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

^a Downgraded two levels due to imprecision: small number of events (n=67) reported across study

^b Downgraded two levels due to imprecision: very few events (n=5) and 95% CI incorporate the potential for benefit, harm and no effect of the intervention

SAE: Two of the four studies in the SAE comparison reporting serious adverse events reported zero events in both arms and so only two studies with 304 participants contributed to the effect estimate.

4. Summary of Findings: Nicotine/vaping reduction compared to minimal support for nicotine vaping cessation

Nicotine/vaping reduction compared to minimal support for nicotine vaping cessation

- Patient or population: people who use nicotine vapes
Setting: USA
Intervention: nicotine/vaping reduction
Comparison: minimal support

Outcomes	Anticipated absolute effects [†] (95% CI)		Relative effect (95% CI)	N ^o of participants (studies)	Certainty of the evidence (GRADE)
	Risk with minimal support	Risk with nicotine/vaping reduction			
Vaping cessation at 6 months or longer follow up: 6 months	Study population 11 per 100	38 per 100 (5 to 100)	RR 3.38 (0.43 to 26.30)	17 (1 RCT)	⊕⊖⊖⊖ Very low ^{a,b}
Change in combustible tobacco use at 6 months or longer – not reported	Study population			No studies reported this outcome	
Number of participants reporting serious adverse events at follow up: range 3 months to 6 months Assessed via self-report and medical records	Study population			No studies reported this outcome	

[†]The estimated number of events in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

^a Downgraded two levels due to risk of bias: the only study contributing to the comparison and outcome was judged to be at high risk of bias

^b Downgraded two levels due to imprecision: extremely low number of events across study arms and 95% CI encompassing the potential for benefit, harm and no effect of the intervention

5. Summary of Findings: Text message-based interventions compared to no/minimal support for nicotine vaping cessation in young people (13-24 years)

Text message-based interventions compared to no/minimal support for nicotine vaping cessation in young people (13-24 years)

- Patient or population: people who use nicotine vapes
Setting: USA
Intervention: text message-based interventions
Comparison: control

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	N ^o of participants (studies)	Certainty of the evidence (GRADE)
	Risk with no/minimal support	Risk with text message-based interventions			
Vaping cessation at 6 months or longer follow up: 6 months	Study population		RR 1.32 (1.19 to 1.47)	4091 (2 RCTs)	⊕⊕⊕⊖ LOW ^a
	22 per 100	29 per 100 (26 to 32)			
Change in combustible tobacco use at 6 months or longer – not reported	Study population		RR 1.03 (0.90 to 1.19)	793 (1 RCT)	⊕⊕⊕⊖ VERY LOW ^{a,b}
	49 per 100	50 per 100 (44 to 58)			
Combustible tobacco use uptake at 6 months or longer among people who did not smoke at baseline	Study population		RR 1.04 (0.81 to 1.33)	1036 (1 RCT)	⊕⊕⊕⊖ VERY LOW ^{a,b}
	19 per 100	20 per 100 (16 to 26)			
Number of participants reporting serious adverse events at follow up: range 3 months to 6 months Assessed via self-report and medical records	Study population		Not pooled**	2082 (3 RCTs)	⊕⊕⊕⊖ LOW ^c
	Not pooled**	Not pooled**			

*The estimated number of events in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

** We did not calculate relative or absolute effects as there were no events across relevant studies and study arms

CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio

^a Downgraded two levels due to indirectness: the contributing studies tested the same intervention in a relatively homogenous population. Unclear if the effects can be generalised to other text message-based interventions and other populations.

^b Downgraded two levels due to imprecision: the CIs demonstrate evidence of clinically significant benefit and clinically significant harm.

^c Downgraded two levels due to imprecision. No events were recorded across study arms.